|
In a classroom analogue study, patients (N= 51) receiving fixed doses of 10 mg, 20 mg or 30 mg ADDERALL XRª demonstrated statistically significant improvements in teacher-rated behavior and performance measures, compared to patients treated with placebo. INDICATIONS
ADDERALL XRª is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The efficacy of ADDERALL XRª in the treatment of ADHD was established on the basis of two controlled trials of children aged 6 to 12 who met DSM-IV criteria for ADHD (see CLINICAL PHARMACOLOGY), along with extrapolation from the known efficacy of ADDERALL ® , the immediate-release formulation of this substance. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e. g., in social, academic, or occupational functioning, and be present in two or more settings, e. g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. Text Continues Below
For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/ careless mistakes;
lack of sustained attention;
poor listener;
failure to follow through on tasks;
poor organization;
avoids tasks requiring sustained mental effort;
loses things;
easily distracted;
forgetful. For the Hyperactive-Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months: fidgeting/ squirming;
leaving seat;
inappropriate running/ climbing;
difficulty with quiet activities;
"on the go";
excessive talking;
blurting answers;
can't wait turn;
intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met. Page: << Prev | 1 | 2 | 3 | 4 | Next >>
|
.gif)
